AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23677743
Drug: Finely crushed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finely crushed OC tablets
Trial: 20137493
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy without antibiotic
Trial: 11426771
Drug: Colforsin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colforsin treatment (0.5 microg.kg(‐1).min(‐1) for 6 hours)
Trial: 11426771
Drug: No colforsin
RxNorm normalized name: Colforsin
DrugBank: Colforsin (DB02587)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No colforsin treatment (control)
Trial: 2597599
Drug: Benfluorex (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benfluorex (three tablets/day) for six months (Group A)
Trial: 5570647
Drug: Phenobarbitone administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbitone administration alongside methyldopa
Trial: 26549958
Drug: Naikan therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naikan therapy (2 hours daily, 5 days a week for 4 weeks)
Trial: 26549958
Drug: Routine medication
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine medication and inpatient rehabilitative treatment (Control)
Trial: 10392328
Drug: Etodolac immediate
RxNorm normalized name: Etodolac
DrugBank: Etodolac (DB00749)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etodolac immediate release (IR) 200 mg
Trial: 10392328
Drug: Etodolac immediate
RxNorm normalized name: Etodolac
DrugBank: Etodolac (DB00749)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etodolac immediate release (IR) 400 mg
Trial: 10392328
Drug: Etodolac extended
RxNorm normalized name: Etodolac Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etodolac extended release (ER) 400 mg
Trial: 10392328
Drug: Etodolac extended
RxNorm normalized name: Etodolac Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etodolac extended release (ER) 1200 mg
Trial: 6394758
Drug: MTX 10
RxNorm normalized name: MTX
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX 10 mg
Trial: 6394758
Drug: MTX 25
RxNorm normalized name: MTX
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX 25 mg
Trial: 6394758
Drug: MTX 10
RxNorm normalized name: MTX
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX 10 mg (after 6 weeks for Group 1)
Trial: 6394758
Drug: MTX 25
RxNorm normalized name: MTX
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX 25 mg (after 6 weeks for Group 2)
Trial: 6394758
Drug: MTX 25
RxNorm normalized name: MTX
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX 25 mg (after 6 weeks for Group 3)
Trial: 21298835
Drug: Packed rice-oral
RxNorm normalized name: red yeast rice Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Packed rice-oral rehydration solution (R-ORS)
Trial: 21298835
Drug: Glucose-based oral
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-based oral rehydration solution (G-ORS)
Trial: 17621994
Drug: Soyfem (standardized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soyfem (standardized isoflavones extract) 52-104 mg/24h, administered as 1 or 2 tablets twice a day
Trial: 3890640
Drug: Initial phase
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial phase of chemotherapy (streptomycin, isoniazid, rifampicin, and pyrazinamide)
Trial: 3890640
Drug: Continuation phase
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation phase of chemotherapy
Trial: 26998705
Drug: Control-Intervention (CI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control-Intervention (CI) group received hourly alerts to get up during work hours
Trial: 26998705
Drug: Control-Control (CC)
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control-Control (CC) group maintained normal behaviors
Trial: 22223819
Drug: Rituximab (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (4 weekly infusions of 375 mg/m(2))
Trial: 19192455
Drug: OROS methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS methylphenidate (36 mg/day, 54 mg/day, 72 mg/day, 90 mg/day)
Trial: 19192455
Drug: OROS methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS methylphenidate (maximally effective dose)
Trial: 12356630
Drug: BQ‐123 (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BQ‐123 (selective blocker of ET(A) receptors)
Trial: 12356630
Drug: ET‐1 (exogenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ET‐1 (exogenous infusion)
Trial: 12356630
Drug: BQ‐123 and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BQ‐123 and BQ‐788 (coinfusion of selective blockers of ET(A) and ET(B) receptors)
Trial: 10471426
Drug: Remacemide hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Remacemide (DB06458)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remacemide hydrochloride 100 mg BID (2 intravenous infusions followed by 6 days' oral treatment)
Trial: 10471426
Drug: Remacemide hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Remacemide (DB06458)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remacemide hydrochloride 200 mg BID or higher
Trial: 10471426
Drug: Remacemide hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Remacemide (DB06458)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remacemide hydrochloride 400 mg BID
Trial: 10471426
Drug: Remacemide hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Remacemide (DB06458)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remacemide hydrochloride 500 mg BID
Trial: 10471426
Drug: Remacemide hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Remacemide (DB06458)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remacemide hydrochloride 600 mg BID
Trial: 8938005
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of frame aspect ratio and pictorial depth
Trial: 31553228
Drug: Toutongning (TTN)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toutongning (TTN) capsule (1200 mg, three times daily)
Trial: 26817912
Drug: Capecitabine plus
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine plus oxaliplatin (capecitabine 1000 mg/m bid on days 1-10 and oxaliplatin 85 mg/m on day 1, every 2 weeks) followed by docetaxel plus capecitabine (docetaxel 30 mg/m on days 1 and 8, capecitabine 825 mg/m bid on days 1-14, every 3 weeks)
Trial: 22241923
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab and low-dose transpupillary thermotherapy (TTT)
Trial: 22241923
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab and low-dose TTT
Trial: 20631453
Drug: iv cibenzoline
RxNorm normalized name: cibenzoline
DrugBank: Cibenzoline (DB13358)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv cibenzoline (70 mg)
Trial: 20631453
Drug: iv disopyramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv disopyramide (50 mg)
Trial: 15907672
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (antibiotics, corticosteroids, 0.9% sodium chloride solution, local decongestants, n=21)
Trial: 15907672
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (n=21)
Trial: 10180750
Drug: Fluconazole (FLU)
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole (FLU) administered intravenously
Trial: 10180750
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B (AMB) administered intravenously
Trial: 10180750
Drug: Fluconazole (FLU)
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole (FLU) administered intravenously for 7 days then orally
Trial: 2651177
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg pirprofen capsules
Trial: 27815771
Drug: Multicomponent inpatient
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent inpatient program (4+4 days) consisting of Acceptance and Commitment Therapy, physical training, and work-related problem-solving.
Trial: 27815771
Drug: Outpatient program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient program (6 sessions during 6 weeks) primarily consisting of Acceptance and Commitment Therapy.
Trial: 10214566
Drug: Surgical procedure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical procedure without ADCON-L (Control)
Trial: 7717485
Drug: Lignocaine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine 0.5 mg.kg‐1
Trial: 7717485
Drug: Lignocaine 1
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine 1 mg.kg‐1
Trial: 31812307
Drug: Phenytoin spray
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenytoin spray 2% for 8 weeks
Trial: 31812307
Drug: Phenytoin spray
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenytoin spray 2%
Trial: 12220747
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment from family physician
Trial: 8560162
Drug: N-acetyl-aspartyl-glutamic acid
RxNorm normalized name: acetyl glutamic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl-aspartyl-glutamic acid (NAAGA) nasal spray, one puff per nostril, four times daily, for 3 weeks
Trial: 8560162
Drug: Disodium cromoglycate
RxNorm normalized name: Disodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium cromoglycate (DSCG) nasal spray, one puff per nostril, four times daily, for 3 weeks
Trial: 8560162
Drug: N-acetyl-aspartyl-glutamic acid
RxNorm normalized name: acetyl glutamic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl-aspartyl-glutamic acid (NAAGA) nasal spray
Trial: 8560162
Drug: Disodium cromoglycate
RxNorm normalized name: Disodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium cromoglycate (DSCG) nasal spray
Trial: 2672925
Drug: Amiprilose HCl,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiprilose HCl, 6 g/d
Trial: 30747908
Drug: NKTR-181 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NKTR-181 100 to 400 mg every 12 hours
Trial: 25064487
Drug: Hand massage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hand massage therapy
Trial: 22130790
Drug: Topical formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical formulation of griseofulvin with TPGS and ethanol
Trial: 22130790
Drug: Topical formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical formulation of griseofulvin
Trial: 19394033
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration solution plus racecadotril (OR + R)
Trial: 19394033
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration solution (OR)
Trial: 15151947
Drug: SRL172 (killed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRL172 (killed Mycobacterium vaccae) with chemotherapy
Trial: 12593029
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (cefotaxime, ceftriaxone, amoxicillin/clavulanate)
Trial: 9649142
Drug: Doxorubicin 75
RxNorm normalized name: DOXOrubicin 75 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 75 mg/m² i.v. every 3 weeks
Trial: 9649142
Drug: Epirubicin 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 90 mg/m² i.v. every 3 weeks
Trial: 2642543
Drug: 6 months
RxNorm normalized name: leuprolide 45 mg/6 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 months of COMP therapy (cyclophosphamide, vincristine, methotrexate, and prednisone)
Trial: 2642543
Drug: 18 months
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 18 months of COMP therapy (cyclophosphamide, vincristine, methotrexate, and prednisone)
Trial: 55529
Drug: Levamisole (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole (150 mg orally three times a week on alternate weeks)
Trial: 31415063
Drug: Home-based exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based exercise intervention (strength/resistance training twice per week and 180 minutes of walking per week)
Trial: 21276962
Drug: Wait-list group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wait-list group (treatment-as-usual, TAU)
Trial: 18759522
Drug: Dalteparin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin (100 IU/kg subcutaneously twice a day for 10 days, then 100 IU/kg once a day for another 10 days)
Trial: 18759522
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg daily throughout the study)
Trial: 12374537
Drug: Daily application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily application of a standard sun protection factor 15+ broad-spectrum retail sunscreen to the head and neck, arms, and hands.
Trial: 499311
Drug: Desmethylimipramine (DMI)
RxNorm normalized name: Desmethylimipramine
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desmethylimipramine (DMI) 75 mg daily for 3 days
Trial: 499311
Drug: Methyldopa 750
RxNorm normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methyldopa 750 mg
Trial: 499311
Drug: Tricyclic antidepressant
RxNorm normalized name: Tricyclic antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tricyclic antidepressant drugs
Trial: 31022754
Drug: Plasma sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma sodium concentration ≤136 mmol/L
Trial: 29460813
Drug: 1000 μg
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 μg vitamin B12 daily for 8 weeks
Trial: 26790758
Drug: LPS administration
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPS administration (0.4–0.8 ng/kg body weight)
Trial: 20642382
Drug: drospirenone +
RxNorm normalized name: Drospirenone
DrugBank: Drospirenone (DB01395)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: drospirenone + ethinylestradiol + oral L-arginine (4 g × 2/daily)
Trial: 8444226
Drug: 5 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml/kg of 20% albumin infusion
Trial: 8444226
Drug: 5 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml/kg of maintenance fluids (placebo)
Trial: 3942669
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of water with diazepam tablets (group A)
Trial: 3942669
Drug: 50 ml
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 ml of water with diazepam tablets (group B)
Trial: 27354129
Drug: Sulfasalazine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfasalazine (1000 mg orally twice daily during and for 4 weeks after RT)
Trial: 27354129
Drug: Placebo (orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (orally twice daily during and for 4 weeks after RT)
Trial: 20080466
Drug: VEGF-targeting drugs
RxNorm normalized name: rhuMAb-VEGF
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: VEGF-targeting drugs (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib)
Trial: 20080466
Drug: PI3K‐mTOR inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PI3K‐mTOR inhibitors (temsirolimus, everolimus)
Trial: 15812585
Drug: Gonyautoxin infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonyautoxin infiltration (100 units in 1 ml)
Trial: 8882257
Drug: Aspiration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspiration of 2 ml of patient's blood into propofol
Trial: 8882257
Drug: Lignocaine 20
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine 20 mg added to propofol
Trial: 8882257
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 2 ml added to propofol
Trial: 3918653
Drug: 16.64 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16.64 mg glyceryl trinitrate
Trial: 3918653
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg isosorbide dinitrate
Trial: 29808262
Drug: 25 ml
RxNorm normalized name: ethanol 6.025 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 ml of 0.25% levobupivacaine + 1 ml (20 mg) nalbuphine
Trial: 29808262
Drug: 25 ml
RxNorm normalized name: ethanol 6.025 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 ml of 0.5% levobupivacaine + 1 ml normal saline
Trial: 29808262
Drug: 25 ml
RxNorm normalized name: ethanol 6.025 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 ml of 0.25% levobupivacaine + 1 ml normal saline
Trial: 26939572
Drug: GSK672 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK672 90 mg twice daily
Trial: 26939572
Drug: GSK672 10-90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK672 10-90 mg twice daily
Trial: 23819250
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment and routine western medicine
Trial: 21838089
Drug: Micronized tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Micronized tretinoin gel 0.05%
Trial: 19480872
Drug: Hippotherapy (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hippotherapy (12 weekly sessions)
Trial: 27016618
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg IV-TXA
Trial: 27016618
Drug: 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg IV-TXA
Trial: 24193993
Drug: 100 or
RxNorm normalized name: Stalevo 100 Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 or 200 mg of lidocaine injections
Trial: 24193993
Drug: saline injections
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: saline injections
Trial: 23535609
Drug: Prenatal lipid-based
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal lipid-based nutrient supplements (LNSs)
Trial: 23535609
Drug: Multiple micronutrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple micronutrient tablets
Trial: 18219348
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) daily for 20 days
Trial: 21033082
Drug: Taurine treatment
RxNorm normalized name: Taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Taurine treatment for NAFLD
Trial: 16282543
Drug: PCK1‐232G/G genotype
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCK1‐232G/G genotype
Trial: 7990065
Drug: Non-hypnotic sessions
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-hypnotic sessions (3 sessions)
Trial: 26980216
Drug: Percutaneous para‐aneurysmal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous para‐aneurysmal saline injection
Trial: 22337474
Drug: Dead Sea
RxNorm normalized name: Cleanser Topical application Soap [MG217 DEAD SEA SOAP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dead Sea salt (DSS) irrigations and DSS nasal spray
Trial: 22337474
Drug: Fluticasone spray
RxNorm normalized name: fluticasone Metered Dose Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone spray and hypertonic saline irrigation and spray
Trial: 18419328
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine gel (11 mL)
Trial: 18419328
Drug: 40% DMSO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40% DMSO with lidocaine (10 mL)
Trial: 12463727
Drug: Roxifiban (XV459)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxifiban (XV459) 0.5 to 1.25 mg daily for 7 to 10 days
Trial: 10348512
Drug: mylohyoid nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mylohyoid nerve block + IAN block (1.8 mL of 2% lidocaine with 1:100,000 epinephrine + 3.6 mL of 2% lidocaine with 1:100,000 epinephrine)
Trial: 10348512
Drug: mock mylohyoid
RxNorm normalized name: mockernut extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mock mylohyoid nerve block + IAN block (3.6 mL of 2% lidocaine with 1:100,000 epinephrine)
Trial: 10348512
Drug: mylohyoid nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mylohyoid nerve block + mock IAN block (1.8 mL of 2% lidocaine with 1:100,000 epinephrine)